Early Stage Researcher
Metagenomic and metabolomics analysis of microbiota intervention therapies of non-alcoholic fatty liver disease in vivo models in the BestTreat program
Building a Gut Microbiome Engineering Toolbox for In-Situ Therapeutic Treatments for Non-alcoholic Fatty Liver Disease (BestTreat) is a program funded by the European Commission which aims to develop novel diagnostic and therapeutic methods for NAFLD based on gut microbiota.
Aim of my study is to investigate the association between the NAFLD progression and alterations in gut microbiota and metabolites. Correlations between metagenomics, metabolomics, imaging data and other prognostic biomarkers for NAFLD are investigated to elucidate the mechanisms behind metabolic benefits conveyed by specific functional strains of the gut microbiota to the pathophysiology and pathogenesis of NAFLD. Metagenomic and metabolomic signatures of specific gut microbiota and metabolites will be used to develop novel microbiome-based disease prognostic biomarkers and therapeutic interventions for NAFLD.
School of Medicine, Institute of Public Health and Clinical Nutrition